Every 10-Q that Avantor, Inc. (AVTR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTR filings page.
Avantor, Inc. (AVTR) reported a Q3 2025 net loss of $711.8 million, driven by a non‑cash, non‑deductible $785.0 million goodwill impairment in its Distribution reporting unit. Net sales were $1,623.8 million, down 5.3% year over year as organic net sales decreased 4.7%. Gross profit was $526.5 million and operating loss was $648.8 million.
Adjusted Operating Income was $237.3 million for the quarter, with Laboratory Solutions at $123.6 million and Bioscience Production at $127.7 million. Year‑to‑date, net cash provided by operating activities was $471.1 million. On the balance sheet, total assets were $11,675.9 million and total debt was $3,857.9 million.
During the quarter, the company made an optional prepayment of $457.4 million on its 2.625% secured notes. Subsequent to quarter‑end, Avantor issued €400.0 million and €550.0 million senior secured term loans (maturing in 2030 and 2032) and amended its revolving credit facility to $1,400.0 million. The Board authorized up to $500.0 million of common stock repurchases.